Gavi's response

Respond and protect: With COVID-19 now reported in almost all Gavi-eligible countries, the Vaccine Alliance is providing immediate funding to health systems, enabling countries to protect health care workers, perform vital surveillance and training, and purchase diagnostic tests.

Maintain, restore and strengthen: Gavi will support countries to adapt and restart immunisation services, rebuild community trust and catch up those who have been missed both before and during the pandemic, while also investing in strengthening immunisation systems to be more resilient and responsive to the communities they serve.

Ensure global equitable access: Gavi is co-leading COVAX, the global effort to securing a global response to COVID-19 that is effective and fair, using its unique expertise to help identify and rapidly accelerate development, production and delivery of COVID-19 vaccines so that anyone that needs them, gets them.

Situation reports

A regular update concerning the impact of and response to the COVID-19 pandemic in Gavi-supported countries.

COVAX Facility

Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19 vaccines.

Learn more

COVAX Facility

Key news

Scientists around the world are working faster than ever to develop and produce vaccines that can stop the spread of COVID-19. Since the emergence of this novel coronavirus in December 2019, several vaccines have started to be rolled out. Here is…

Gavi’s long-term approach to developing healthy markets for critical vaccines has led to greater stability and security, providing countries with the confidence that supplies will be available to meet their demand.

In 2019, a higher share of Gavi-supported countries than ever before met their co-financing obligations on time, thanks to strong political commitment.

In 2019, countries delivered more than 230 million routine vaccinations, a record number, supported by unprecedented levels of health system funding from Gavi to support immunisation and protect the most vulnerable children. Here is what Gavi did…

The goal of our market shaping work is to help ensure vaccine markets work better for lower-income countries. We want the maximum number of people to receive the life-saving and health-protecting benefits of immunisation.

After transitioning out of Gavi support in 2017, the Republic of Moldova is mobilising champions and advocates to strengthen vaccine confidence – which is crucial to the success and sustainability of immunisation programmes.

Typhoid fever is increasingly resistant to the main antibiotics used to treat it. Gavi is supporting a new vaccine to help control this deadly disease – and fight antimicrobial resistance.

September 2020 marks the 75th anniversary of the United Nations General Assembly (UNGA). This year, the focus of the high-level General Debate is the importance of effective multilateralism.

Snapshots from DRC, India and Zambia illustrate country ownership and progress in the fights against Ebola, polio and HPV.

COVID-19 explored

View all

The pandemic has strained most countries’ health systems. Afghanistan has faced more hurdles than most.

We didn’t have to be stuck with needles.

Study suggests the risk of a serious brain clot is up to ten times higher in people with COVID-19 infections, compared to those receiving a COVID-19 vaccine.

COVAX has a critical role to play in ending the acute phase of the pandemic. The initiative could also be a model for how we address some of the most urgent development challenges of our time, from climate change to poverty reduction.

The delivery of vaccines has gone a long way to alleviating the fears and pressure on healthcare workers in Eswatini.

Last updated: 31 Mar 2021

Subscribe to our newsletter